Press Releases

Date Title and Summary Additional Formats
Toggle Summary Assembly Biosciences Announces Oral Presentation at 2018 AASLD
SAN FRANCISCO , Oct. 02, 2018 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (NASDAQ: ASMB), a clinical-stage biotechnology company developing innovative therapeutics targeting hepatitis B virus (HBV) and diseases associated with the microbiome, today announced that the company will have an oral
View HTML
Toggle Summary Assembly Biosciences to Present at Upcoming Investor Conferences
SAN FRANCISCO , Aug. 28, 2018 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (NASDAQ: ASMB), today announced that the company will be participating in the following upcoming investor conferences in September: Baird Global Healthcare Conference : Uri Lopatin , MD, Chief Medical Officer, will
View HTML
Toggle Summary Assembly Biosciences Announces Second Quarter 2018 Financial Results
-  ABI-H0731 Phase 2a Clinical Trials Actively Enrolling Patients; Initial Data Continues to be Anticipated in H1 2019 -  Strong Balance Sheet Provides Significant Runway SAN FRANCISCO and INDIANAPOLIS , Aug. 08, 2018 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc.
View HTML
Toggle Summary Assembly Biosciences Announces FDA Fast Track Designation Granted to ABI-H0731 for the Treatment of Hepatitis B Virus Infection
INDIANAPOLIS and SAN FRANCISCO, July 25, 2018 (GLOBE NEWSWIRE) -- Assembly Biosciences , Inc. (NASDAQ:ASMB) today announced that the U.S. Food and Drug Administration ( FDA ) has granted Fast Track designation to ABI-H0731 for the treatment of patients with chronic Hepatitis B infection.
View HTML
Toggle Summary Assembly Biosciences Announces the Closing of its Offering of Common Stock and Full Exercise of the Underwriters’ Option to Purchase Additional Shares
INDIANAPOLIS and SAN FRANCISCO , July 16, 2018 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq:ASMB) (“Assembly”), today announced the closing of its previously announced underwritten public offering of 4,600,000 shares of its common stock to the public at $36.00 per share, which included
View HTML
Toggle Summary Assembly Biosciences Announces Pricing of $144 Million Offering of Common Stock
INDIANAPOLIS and SAN FRANCISCO , July 11, 2018 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq:ASMB) (“Assembly”), today announced the pricing of an underwritten public offering of 4,000,000 shares of its common stock to the public at $36.00 per share.
View HTML
Toggle Summary Assembly Biosciences Announces Proposed Underwritten Offering of Common Stock
INDIANAPOLIS and SAN FRANCISCO , July 10, 2018 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq:ASMB) (“Assembly”), today announced that it intends to offer and sell, subject to market and other conditions, 3,000,000 shares of its common stock in an underwritten public offering.
View HTML
Toggle Summary Assembly Biosciences Initiates Two Phase 2a Trials of ABI-H0731 for the Treatment of Hepatitis B Virus Infection
Key aim is to demonstrate that core inhibitor therapy combined with standard of care antivirals can offer curative potential for HBV INDIANAPOLIS and SAN FRANCISCO, July 09, 2018 (GLOBE NEWSWIRE) --   Assembly Biosciences, Inc.  (Nasdaq:ASMB), today announced the initiation of two multi-center,
View HTML
Toggle Summary Assembly Biosciences to Host Research and Development Day on Wednesday, June 20, 2018
Live event and webcast to focus on the potential of curative therapy for HBV infection and feature presentations from two liver medicine specialists INDIANAPOLIS and SAN FRANCISCO, June 13, 2018 (GLOBE NEWSWIRE) -- Assembly Biosciences , Inc. (NASDAQ:ASMB), a clinical-stage biotechnology company
View HTML
Toggle Summary Assembly Biosciences Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
INDIANAPOLIS and SAN FRANCISCO , June 08, 2018 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (NASDAQ:ASMB) a clinical-stage biotechnology company advancing a new class of oral therapeutics for the treatment of hepatitis B virus (HBV) infection and novel oral synthetic live biotherapeutics for
View HTML